INVENTIVA (EPA:IVA) Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
Transparency directive : regulatory news
15/11/2024 22:00
source : webdisclosure.com
INVENTIVA 's latest news
17/12/2024 22:00
12/12/2024 22:00
21/11/2024 22:00
20/11/2024 22:00
20/11/2024 22:00
15/11/2024 22:00
30/10/2024 21:00
21/10/2024 14:30
14/10/2024 19:45
31/07/2024 22:00
Other stories
26/12/2024 11:34
26/12/2024 11:33
26/12/2024 11:04
26/12/2024 09:37
26/12/2024 08:00
26/12/2024 01:05
26/12/2024 03:22
26/12/2024 12:08
26/12/2024 10:53
26/12/2024 11:35
25/12/2024 23:06
26/12/2024 07:09
26/12/2024 10:55
24/12/2024 20:10
26/12/2024 08:15
26/12/2024 06:00
26/12/2024 09:27
26/12/2024 01:01
26/12/2024 11:39
25/12/2024 08:03
25/12/2024 09:55
25/12/2024 07:05
25/12/2024 21:26
26/12/2024 09:25
26/12/2024 10:07
25/12/2024 19:10
26/12/2024 12:21
26/12/2024 11:00
26/12/2024 09:00
26/12/2024 11:41
24/12/2024 15:20
24/12/2024 15:56
24/12/2024 20:00
25/12/2024 13:22
26/12/2024 00:56
26/12/2024 08:00
25/12/2024 09:00
26/12/2024 10:50